Abstract:Background Epidemiological studies show that women are generally at lower risk for cardiovascular disease than men. Here, we investigated the sex‐specific differential effect of genetically increased low‐density lipoprotein cholesterol (LDL‐C) on cardiovascular disease (CVD) and other lipid‐associated diseases. Methods and Results This is a 2‐sample Mendelian randomization study that uses individual participant data from 425 043 participants from the UK Biobank, including 229 279 female participants. An 80‐variant LDL‐C weighted genetic score was generated. Linear and logistic regression models with interactions were used to identify differences between sex‐specific LDL‐C effects on lipids, carotid‐intima media thickness, and multiple cardiovascular outcomes such as CVD, ischemic heart disease, peripheral artery disease, heart failure, aortic valve disease, type 2 diabetes, atrial fibrillation, and aortic aneurysm and dissection. After correction for multiple testing, we observed that the genetically increased LDL‐C effect on CVD events was sex specific: per SD genetically increased LDL‐C, female participants had a higher LDL‐C increase but an attenuated CVD risk increase compared with male participants (LDL‐C: female participants 0.71 mmol/L, 95% CI, 0.70–0.72 and male participants 0.57 mmol/L, 95% CI, 0.56–0.59. P for interaction: 5.03×10 −60 ; CVD: female participants: odds ratio [OR], 1.32; 95% CI 1.24–1.40 and male participants: OR, 1.52; 95% CI, 1.46–1.58. P for interaction: 9.88×10 −5 ). We also observed attenuated risks for ischemic heart disease and (nominally for) heart failure in female participants, and genetically increased LDL‐C results in higher risk for aortic valve disease in female participants compared with male participants. Genetically increased LDL‐C was also associated with an attenuated carotid‐intima media thickness increase in female participants. We did not observe other significant attenuations. Sensitivity analyses with an unweighted genetic score and sex‐specific weighted genetic scores showed similar results. Conclusions We found that genetically increased LDL‐C has a sex‐specific differential effect on the risk for cardiovascular disease, ischemic heart disease, heart failure, and aortic valve stenosis. Our observations provide evidence that LDL‐C might be a less important determinant of CVD in women compared with men, suggesting that male patients might benefit more from LDL‐C targeted therapies for CVD management than female patients and warranting investigations into the sex‐specific relative contribution of risk factors for CVD. Nonstandard Abbreviations and Acronyms AVS aortic valve stenosis cIMT carotic intima media thickness CTT Cholesterol Treatment Trialists' Collaboration MR Mendelian randomization Clinical Perspective What Is New? Observational data have shown that female patients are at lower risk for cardiovascular disease than male patients. Using Mendelian randomization in the UK Biobank, we observe that the causal effect of low‐density lipoprotein cholesterol on cardiovascular disease is stronger in male than in female participants. We also observed that the causal effect of low‐density lipoprotein cholesterol on aortic valve stenosis is stronger in female than in male participants. What Are the Clinical Implications? Our observations warrant more research into the sex‐specific attributions of risk factors for cardiovascular and related diseases. Male patients might benefit more from low‐density lipoprotein cholesterol targeted therapies than female patients. Sex‐differential effects should be taken into account in the design of clinical trials. Cardiovascular disease (CVD) remains a major cause of morbidity and mortality, 1 and lowering plasma concentrations of low‐density lipoprotein cholesterol (LDL‐C) is the cornerstone in CVD prevention, irrespective of the sex of the patient at risk. Observational data have shown, however, that women are at lower risk for CVD than men. 2 The sex differential CV -Abstract Truncated-

07 - GENDER-SPECIFIC DIFFERENCES AT BOTH EXTREME ENDS OF THE LDL CHOLESTEROL DISTRIBUTION CURVE

Impact of Lipoprotein(a) Level on Low-Density Lipoprotein Cholesterol- or Apolipoprotein B-Related Risk of Coronary Heart Disease

Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia

LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia

Performance of LDL-C only compared to the Dutch Lipid Clinic Network Score for screening of familial hypercholesterolaemia: the Austrian experience and literature review

Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart Study.

Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting

Impact of Lp(a) on lipid control in patients with acute coronary syndrome

The prevalence of hyperlipoproteinemia(a) in outpatient cardiology clinic patients of European ancestry: results from a STAR-Lp(a) cross-sectional study

Epidemiology of atherosclerotic cardiovascular disease in polygenic hypercholesterolemia with or without high lipoprotein(a) levels

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol

Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.

Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan area of Brandenburg, Germany

Lipoprotein(a) Is Markedly More Atherogenic Than LDL

Sex Differences in the Presentation, Treatment and Outcomes of Patients with Homozygous Familial Hypercholesterolemia

Considerations for routinely testing for high Lp(a)

Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity

Lipoprotein(A) Levels And Genetic Polymorphisms In Lpa Genes May Contribute To Risk Of Coronary Heart Disease

Low‐Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific

Lipoprotein (a) testing patterns among subjects with a measured lipid panel: The Mayo Clinic experience